331 related articles for article (PubMed ID: 21586916)
1. Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report.
Golubchik P; Sever J; Weizman A; Zalsman G
Clin Neuropharmacol; 2011; 34(3):108-10. PubMed ID: 21586916
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
[TBL] [Abstract][Full Text] [Related]
3. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
5. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
Golubchik P; Sever J; Zalsman G; Weizman A
Int Clin Psychopharmacol; 2008 Jul; 23(4):228-31. PubMed ID: 18446088
[TBL] [Abstract][Full Text] [Related]
6. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
[TBL] [Abstract][Full Text] [Related]
7. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.
Manor I; Rozen S; Zemishlani Z; Weizman A; Zalsman G
Clin Neuropharmacol; 2011; 34(4):148-54. PubMed ID: 21738027
[TBL] [Abstract][Full Text] [Related]
8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
9. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
10. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
11. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
13. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
Levin FR; Evans SM; Brooks DJ; Garawi F
Drug Alcohol Depend; 2007 Feb; 87(1):20-9. PubMed ID: 16930863
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.
Golubchik P; Golubchik L; Sever JM; Weizman A
Int Clin Psychopharmacol; 2014 Sep; 29(5):274-8. PubMed ID: 24743562
[TBL] [Abstract][Full Text] [Related]
16. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?
Golubchik P; Kodesh A; Weizman A
Clin Neuropharmacol; 2013; 36(5):141-5. PubMed ID: 24045603
[TBL] [Abstract][Full Text] [Related]
17. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of methylphenidate on performance during the Test of Variables of Attention in children with attention deficit/hyperactivity disorder.
Huang YS; Chao CC; Wu YY; Chen YY; Chen CK
Psychiatry Clin Neurosci; 2007 Jun; 61(3):219-25. PubMed ID: 17472588
[TBL] [Abstract][Full Text] [Related]
20. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
